Medherant

Terrapin Pharmacy Rebrands as Altruix, Bringing State-of-The-Art Medication Adherence Technology to the Behavioral Health Pharmacy Brand

Retrieved on: 
Tuesday, August 15, 2023
Operation, Doctor of Pharmacy, Business, DSM-IV codes, Medicine, Disability studies, IDD, Risk, Altruism, SUD, Factitious disorder, Approximation error, Hospital, Nursing, MD, Medherant

ANNAPOLIS, Md., Aug. 15, 2023 /PRNewswire/ -- Terrapin Pharmacy, located in Annapolis, MD, today announced that it is changing its name to Altruix. Altruix consists of the combined operations of the now former Terrapin Pharmacy, Bank's Apothecary, and Altruix in Lancaster (formerly Ganse Apothecary), serving over 23,000 customers across 23 states. By combining three local, independent pharmacy organizations, Altruix is able to offer access to expanded personalized pharmacy services and more behavioral health, substance use disorder (SUD), and intellectual and developmental disability (IDD) medications.

Key Points: 
  • By combining three local, independent pharmacy organizations, Altruix is able to offer access to expanded personalized pharmacy services and more behavioral health, substance use disorder (SUD), and intellectual and developmental disability (IDD) medications.
  • Medherent is a remote medication adherence platform built specifically for individuals with behavioral health conditions or intellectual & developmental disabilities.
  • It also improves adherence, decreases emergency department (ED) and hospital costs, reduces medication errors, and results in fewer ED visits.
  • The Annapolis Altruix location serves the greater Annapolis region and surrounding communities as a long-term care pharmacy, providing pharmacy expertise and access to medications for behavioral health, SUD, and IDD providers.

Cycle Pharmaceuticals and Medherant Partner to Develop Medicines using the TEPI Patch® Technology

Retrieved on: 
Tuesday, May 5, 2020
Medical devices, Health, Research, Pharmaceutical, Science, Biotechnology, Medherant, Routes of administration, Health, Drug delivery, Transdermal, Adhesive, Cycle Pharmaceuticals, Medherant

Cycle Pharmaceuticals Ltd (Cycle) and Medherant Ltd (Medherant) are pleased to announce that they have signed an agreement to develop and commercialize multiple products using the TEPI Patch technology.

Key Points: 
  • Cycle Pharmaceuticals Ltd (Cycle) and Medherant Ltd (Medherant) are pleased to announce that they have signed an agreement to develop and commercialize multiple products using the TEPI Patch technology.
  • View the full release here: https://www.businesswire.com/news/home/20200504005647/en/
    Cycle will utilise Medherants proprietary TEPI Patch transdermal delivery technology to develop formulations that will address patients unmet needs such as dysphagia and dyskinesia, further expanding its pipeline.
  • Following TEPI Patch formulation development by Medherant, Cycle will be responsible for clinical development and registration, and will commercialise the products arising from this collaboration.
  • Medherant has built upon its founders world-leading expertise in bio-adhesives and polymer chemistry to create its unique patent protected TEPI Patch drug delivery technology.